- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02011750
Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii Infection in Early Course Schizophrenia
Pilot Trial of Valproate as Adjunctive Treatment for Toxoplasma Gondii
This is an exploratory study in Egypt that will combine a treatment trial among early course schizophrenia (ECSZ) patients with key analyses suggested by rodent studies. Specifically, the study will test the provocative results from animal studies indicating an impact of Toxoplasma Gondii (TOX) exposure on novelty seeking. The study will also test whether exposure to TOX is associated with other cognitive and behavioral changes, as well as changes in overall social function. We will also explore the relative efficacy of Sodium Valproate (Depakote, DEP) in improving clinical and overall social function among TOX exposed and unexposed patients.
Hypotheses
- At baseline, TOX exposure is associated with increased novelty seeking, clinical severity, and impaired cognitive and overall social function in patients with SZ.
- Adjunctive DEP treatment improves clinical symptoms, cognitive and social function in SZ, particularly among TOX exposed SZ patients.
- Exploratory hypothesis: adjunctive DEP reduces serological indices of TOX infection (VIP and TH levels).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Mansourah, Egypt, 35516
- Mansoura University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent
- Adult men or women (ages 18-50 years)
- Schizophrenia / schizoaffective disorder (DSM IV)
- Duration of illness < 5 years (since onset of psychosis)
- On a stable dose of an antipsychotic for at least a month
- Scores 4 or more on at least one item of the Positive and Negative Syndrome Scale.
Exclusion Criteria:
- Substance abuse in the past month/dependence past 6 months
- History of / or current medical/neurological illnesses e.g. mental retardation (DSM-IV) or epilepsy;
- Medical conditions that are judged by the consulting internist and research staff to be unstable
- Pregnant or breast-feeding women
- Known allergy or serious adverse event to DEP, Received Chlorpromazine, Trimethoprim or DEP for up to 6 months prior to study entry.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Sodium Valproate treatment
Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion.
For the Sodium Valproate treatment grou, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL).
Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued.
Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
|
Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion.
For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL).
Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued.
Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
Other Names:
Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion.
For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL).
Then PLA treatment will continue for 16 more weeks.
Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
|
PLACEBO_COMPARATOR: Placebo
Placebo Comparator: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion.
For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL).
Then PLA treatment will continue for 16 more weeks.
Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
|
Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion.
For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL).
Then PLA treatment will continue for 16 more weeks.
Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Severity
Time Frame: Clinical severity will be assessed during week 20 of the study.
|
Clinical Severity will be measured by the Positive and Negative Syndrome Scale (PANSS),a 7 point rating scale for 30 psychopathological items based on interviews or reports.
|
Clinical severity will be assessed during week 20 of the study.
|
Cognitive Domains assessed via the Arabic version of the Penn CNB
Time Frame: Cognitive domains wil be measured in week 16 of the study
|
Cognitive domains will be assessed using the Arabic version of the Penn Computerized Neuropsychological Battery (CNB), which includes cognitive measures that distinguish SZ cases and relatives from controls.
Accuracy and response time are recorded.
|
Cognitive domains wil be measured in week 16 of the study
|
Social Function assessed via the Quality of Life Scale
Time Frame: Social functioing will be assessed during week during week 16.
|
Overall Social function will be measured by the Quality of Life Scale, which measures interpersonal, social and occupational functioning.
|
Social functioing will be assessed during week during week 16.
|
Cognitive domains assessed via Trails Making Test
Time Frame: Cognitive domains will be assessed in week 16 of the study
|
Cognitive domains will be assessed using the Trails Making Test, a neuropsychological test of attention and task switching.
|
Cognitive domains will be assessed in week 16 of the study
|
Social Function -assessed via the GAF scale
Time Frame: Social functioning will be assessed during week 16
|
Social functioning will be assessed using the Global Assessment of Functioning (GAF), a global measure of function and symptom severity.
|
Social functioning will be assessed during week 16
|
Social Functioning assessed via the Short Form
Time Frame: Social functioning will be assessed during week 16
|
Social functioning will be assessed via the Short Form, a multi-item scale that consists of 8 scaled scores, which are the weighted sums of the questions in their section.
Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight.
|
Social functioning will be assessed during week 16
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Side effects
Time Frame: Side effects will be measured during week 20 of the study.
|
Participants will be monitored for adverse reactions to study medication through week 20.
|
Side effects will be measured during week 20 of the study.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Hader Mansour, MD, University of Pittsburgh
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Infections
- Schizophrenia Spectrum and Other Psychotic Disorders
- Parasitic Diseases
- Coccidiosis
- Protozoan Infections
- Schizophrenia
- Toxoplasmosis
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Enzyme Inhibitors
- Tranquilizing Agents
- Psychotropic Drugs
- GABA Agents
- Anticonvulsants
- Antimanic Agents
- Valproic Acid
Other Study ID Numbers
- PRO12020320
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Schizophrenia
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Organon and CoCompletedSchizophrenia, Paranoid | Schizophrenia, Disorganized | Schizophrenia, Undifferentiated
-
Bradley LegaRecruiting
-
All India Institute of Medical Sciences, BhubaneswarRecruitingTreatment Resistant SchizophreniaIndia
-
King's College LondonSouth London and Maudsley NHS Foundation TrustRecruitingTreatment-resistant Schizophrenia | Healthy Controls | Treatment-responsive SchizophreniaUnited Kingdom
-
University of Sao PauloUnknownRefractory Schizophrenia | Super Refractory SchizophreniaBrazil
-
Ohio State UniversityRecruitingTreatment-resistant SchizophreniaUnited States
-
University Hospital, BrestRecruitingSchizophrenia | Schizophrenia Prodromal | Schizophrenia, ChildhoodFrance
-
NYU Langone HealthNot yet recruitingTreatment-resistant SchizophreniaUnited States
-
Johns Hopkins UniversityNational Institute of Mental Health (NIMH)RecruitingTreatment-resistant SchizophreniaUnited States
Clinical Trials on Sodium Valproate treatment
-
University of BirminghamActive, not recruitingWolfram SyndromeFrance, United Kingdom, Poland, Spain
-
Xijing HospitalUnknownTraumatic Brain InjuryChina
-
All India Institute of Medical Sciences, New DelhiUnknownChronic Lymphocytic LeukemiaIndia
-
Johnson & Johnson Pharmaceutical Research & Development...Completed
-
University of VirginiaTerminatedGlioblastomaUnited States
-
Poznan University of Physical EducationActive, not recruiting
-
Poznan University of Life SciencesPoznan University of PhysEDCompleted
-
Poznan University of Life SciencesPoznan University of PhysEDCompleted
-
University of Roma La SapienzaUnknownCoronary Artery DiseaseItaly
-
Postgraduate Institute of Dental Sciences RohtakUnknownAlveolar Bone LossIndia